ReviewNature reviews. Neurology2009
Advances in the genetics of glioblastoma: are we reaching critical mass?
Review in Nature reviews. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 117 citations in OpenAlex.
- Major Ethnic Populations Are Significantly Differentiated at the Glioblastoma Multiforme Candidate Loci.International journal of molecular sciences · 2026Article
- Insights into brain tumor diagnosis: exploringFrontiers in neurology · 2024Review
- Inhibition of STAT3 signaling as critical molecular event in HUC-MSCs suppressed Glioblastoma Cells.Journal of Cancer · 2023Article
- Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy.Nature communications · 2022Article
- PSMC2 is overexpressed in glioma and promotes proliferation and anti-apoptosis of glioma cells.World journal of surgical oncology · 2022Article
- Inhibiting CK2 among Promising Therapeutic Strategies for Gliomas and Several Other Neoplasms.Pharmaceutics · 2022Review
- Identification of Prognostic Biomarkers of Glioblastoma Based on Multidatabase Integration and Its Correlation with Immune-Infiltration Cells.Journal of oncology · 2022Article
- Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma.International journal of molecular sciences · 2021Article
- UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT.Aging · 2020Article
- Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A.International journal of clinical oncology · 2020Article
- Long noncoding RNA DANCR knockdown inhibits proliferation, migration and invasion of glioma by regulating miR-135a-5p/BMI1.Cancer cell international · 2020Article
- Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.NPJ genomic medicine · 2020Review
- Genetic and Lineage Classification of Glioma-Initiating Cells Identifies a Clinically Relevant Glioblastoma Model.Cancers · 2019Article
- TROY interacts with RKIP to promote glioma development.Oncogene · 2019Article
- Prostate-Specific Membrane Antigen Expression in Neovasculature of Glioblastoma Multiforme.Advanced biomedical research · 2019Article
- Enhanced glioma-targeting and stability ofActa pharmaceutica Sinica. B · 2018Article
- MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.Oncotarget · 2017Article
- UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy.Oncogene · 2017Article
- Degradable Organically-Derivatized Polyoxometalate with Enhanced Activity against Glioblastoma Cell Line.Scientific reports · 2016Article
- Development of bioactive materials for glioblastoma therapy.Bioactive materials · 2016Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma is the most common and highest-grade brain tumor, causing over 10,000 deaths each year in the US alone. Given the resistance of this tumor to standard surgery, radiation and chemotherapy, an understanding of the underlying genetic lesions is vital. Recent efforts to comprehensively profile glioblastomas using the latest technologies, both by The Cancer Genome Atlas (TCGA) project and by other groups, are addressing this need. Some genetic aberrations in glioblastoma have been known for decades, but early output from the new profiling initiatives has further illuminated the relevant genetics in this disease. Some genetic lesions, such as TP53 mutation, NF1 deletion or mutation, and ERBB2 amplification, have been found to be more common than was previously reported. New and unexpected discoveries have also been made, such as frequent mutations of the IDH1 and IDH2 genes in secondary glioblastoma. We might be tempted to speculate that we are approaching a comprehensive knowledge of the genetic lesions involved in glioblastoma, although other major discoveries doubtless remain to be made. In addition, the complex task of incorporating our updated knowledge into new--and possibly personalized--therapies for patients with glioblastoma still lies ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.